Elotuzumab - AbbVie/Bristol-Myers Squibb
Alternative Names: BMS-901608; Empliciti; HuLuc-63; PDL-063Latest Information Update: 18 Apr 2025
At a glance
- Originator PDL BioPharma
- Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Smoldering multiple myeloma
Most Recent Events
- 14 Feb 2025 Bristol-Myers Squibb completes the phase II trial in Multiple myeloma (Second-line or greater therapy, Combination therapy) in USA (IV) (NCT03361306)
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Multiple myeloma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 26 Jan 2024 Dana-Farber Cancer Institute in collaboration with BMS completes a phase-II trial in Multiple myeloma (Combination therapy, First-line therapy, Newly diagnosed) in USA (IV), (NCT02375555),